Holger Neecke
Vorstandsvorsitzender bei Tethis SpA
Profil
Holger Neecke is currently the Chief Executive Officer at Tethis SpA since 2022.
Prior to this, he worked as the Director-Investor Relations at AGC Biologics SpA from 2001 to 2010 and as the Senior Director-Business Development at Ablynx NV.
He completed his undergraduate degree at the University of Basel, his MBA at the University of Bocconi, and his doctorate at the University of Milan.
Aktive Positionen von Holger Neecke
Unternehmen | Position | Beginn |
---|---|---|
Tethis SpA
Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Vorstandsvorsitzender | 20.10.2022 |
Ehemalige bekannte Positionen von Holger Neecke
Unternehmen | Position | Ende |
---|---|---|
ABLYNX | Corporate Officer/Principal | - |
MOLMED S.P.A. | Investor Relations Kontakt | - |
Ausbildung von Holger Neecke
University of Milan | Doctorate Degree |
University of Basel | Undergraduate Degree |
University of Bocconi | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
AGC Biologics SpA
AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Tethis SpA
Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Health Technology |